Abou-Hanna Jacob J, Tiu Teo Honeylen M, Thangavel Rajarathna, Elner Victor M, Demirci Hakan
Department of Ophthalmology and Visual Science, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA.
Orbit. 2022 Jun;41(3):297-304. doi: 10.1080/01676830.2021.1874424. Epub 2021 Jan 21.
To report long-term outcomes of systemic rituximab therapy for idiopathic orbital inflammation (IOI) as both primary and salvage therapy and to review the English literature.
A retrospective review of four consecutive biopsy-proven IOI cases managed with systemic rituximab including demographics, management, and outcomes, and review of English literature, were performed. Primary outcome measures included resolution of symptoms, recurrence, and length of follow up.
Of four cases, systemic rituximab was the first-line therapy in two cases and salvage therapy in two cases. The mean age of the patients was 62 years (range, 50-68 years). The orbit was involved in three cases and extraocular muscle in one case. Systemic rituximab (1 g weekly for 4 weeks) was given for one session in three patients and for 12 sessions in 1 patient. All four patients responded with the resolution of all symptoms without recurrence after at least 5 years of follow up. Review of the literature showed systemic rituximab had provided clinical improvement at shorter follow up in 14 of 15 cases when used as a salvage therapy.
Systemic rituximab therapy seems to be an effective therapy for IOI as salvage or first-line therapy with long-term clinical durability.
报告利妥昔单抗全身治疗作为特发性眼眶炎症（IOI）的一线及挽救治疗的长期疗效，并对英文文献进行综述。
对连续4例经活检证实的IOI病例进行回顾性分析，内容包括人口统计学资料、治疗方法及疗效，并对英文文献进行综述。主要观察指标包括症状缓解情况、复发情况及随访时间。
4例患者中，2例将利妥昔单抗全身治疗作为一线治疗，2例作为挽救治疗。患者平均年龄62岁（范围50 - 68岁）。3例累及眼眶，1例累及眼外肌。3例患者接受1个疗程的利妥昔单抗全身治疗（1g/周，共4周），1例患者接受12个疗程。所有4例患者症状均缓解，且至少随访5年无复发。文献综述显示，利妥昔单抗作为挽救治疗时，15例中有14例在较短随访期内临床症状改善。
利妥昔单抗全身治疗作为IOI的挽救或一线治疗，似乎是一种有效的治疗方法，具有长期临床疗效。
